Time trends in primary HIV-1 drug resistance among recently infected persons

Journal of the American Medical Association

Volumn 288, Issue 2, 2002, Pages 181-188

  Grant, Robert M ^a,b,d   Hecht, Frederick M ^b,d   Warmerdam, Maria ^a,b   Liu, Lea ^b,d   Liegler, Teri ^a   Petropoulos, Christos J ^f   Hellmann, Nicholas S ^f   Chesney, Margaret ^c   Busch, Michael P ^d,e   Kahn, James O ^d  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Blood Centers of the Pacific   (United States)

^f Viro Logic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0037055016     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.2.181     Document Type: Article

References (44)

1. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts
2. Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance
3. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance
4. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
5. Transmission of zidovudine-resistant HIV during a bloody fight
6. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine: Sydney Primary HIV Infection Study Group
7. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus
8. HIV-1 drug resistance in newly infected individuals
9. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
10. Transmission of antiretroviral-drug-resistant HIV-1 variants
11. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
12. Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: Identification and characterization of the source of exposure
13. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
14. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
15. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes
16. Update on drug resistance mutations in HIV-1
17. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants
18. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
19. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
20. Determination of a clinically relevant phenotypic resistance "cutoff" for Abacavir using the PhenoSense assay
21. Identification of clinically relevant phenotypic and genotypic break-points for AbT-378/R in multiple PI-experienced, NNRTI-naive patients
22. CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretrovirat therapy
23. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing
24. Impact of baseline nnRTI resistance on the efficacy of efavirenz combination therapy in nnRTI therapy-naive patients (study DMP 266-006)
25. Impact of moderate decreases in baseline nnRTI susceptibility on response to antiretroviral therapy
26. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
27. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
28. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
29. Viral load and heterosexual transmission of human immunodeficiency virus type 1: Rakai Project Study Group
30. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
31. A shortterm clinical evaluation of L-697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase: L-697,661 Working Group
32. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial: Italy, the Netherlands, Canada and Australia Study
33. Carrier rate of zidovudine-resistant HIV-1: The impact of failing therapy on transmission of resistant strains
34. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
35. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting
36. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
37. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
38. CD4(+) T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite longterm treatment with protease inhibitor-based therapy
39. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia
40. Prevalence of HIV-1 drug resistance muations in 80 newly infected individuals
41. A tale of two futures: HIV and antiretroviral therapy in San Francisco
42. Predicting the unpredictable: Transmission of drug-resistant HIV